Asunto(s)
Amsacrina/uso terapéutico , Enfermedad de Hodgkin/tratamiento farmacológico , Linfoma no Hodgkin/tratamiento farmacológico , Anciano , Amsacrina/efectos adversos , Ensayos Clínicos como Asunto , Evaluación de Medicamentos , Femenino , Enfermedades Hematológicas/inducido químicamente , Enfermedad de Hodgkin/patología , Humanos , Linfoma no Hodgkin/patología , Masculino , Persona de Mediana EdadRESUMEN
The activity of m-AMSA was evaluated IN 39 patients with advanced malignant melanoma. Seventy-nine percent of the patients had some prior chemotherapy. The others had some combination of surgery, radiotherapy, and immunotherapy prior to this study. Patients were treated every 3 weeks starting with 60 or 120 mg/m2 of m-AMSA depending on the extent of prior treatment. Doses were escalated if nadir WBC counts were greater than 2500/microliter. Leukopenia was the dose-limiting toxicity with 7.5% of patients having nadir WBC counts less than 1000/microliter. Of the 39 patients evaluable for response, all had progressive disease. In this study, m-AMSA in myelosuppressive doses was not active in malignant melanoma.
Asunto(s)
Aminoacridinas/uso terapéutico , Antineoplásicos/uso terapéutico , Melanoma/tratamiento farmacológico , Adulto , Anciano , Aminoacridinas/efectos adversos , Amsacrina , Antineoplásicos/efectos adversos , Evaluación de Medicamentos , Femenino , Humanos , Leucopenia/inducido químicamente , Neoplasias Pulmonares/secundario , Metástasis Linfática , Masculino , Persona de Mediana Edad , Náusea/inducido químicamente , Neoplasias Cutáneas/secundario , Trombocitopenia/inducido químicamenteAsunto(s)
Aminoacridinas/uso terapéutico , Antineoplásicos/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Adulto , Anciano , Aminoacridinas/administración & dosificación , Aminoacridinas/efectos adversos , Amsacrina , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Esquema de Medicación , Evaluación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Adenocarcinoma/tratamiento farmacológico , Aminoacridinas/administración & dosificación , Neoplasias Renales/tratamiento farmacológico , Adulto , Anciano , Aminoacridinas/efectos adversos , Amsacrina , Médula Ósea/efectos de los fármacos , Evaluación de Medicamentos , Femenino , Humanos , Leucopenia/inducido químicamente , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/secundario , Masculino , Persona de Mediana Edad , Neoplasias Pleurales/tratamiento farmacológico , Neoplasias Pleurales/secundario , Trombocitopenia/inducido químicamenteRESUMEN
A patient with lymphosarcoma cell leukemia resistant to chemotherapy was treated with filtration leukapheresis and centrifugation leukapheresis. Filtration leukapheresis removed only 10(11) leukemia cells per 8.5 liters of blood processed, while centrifugation leukapheresis removed approximately six times as many leukemia cells from the same amount of blood. Lymph nodes and spleen diminished in size and the WBC count decreased after nine treatments. However, the patient remained markedly thrombocytopenic, and his bone marrow remained infiltrated with lymphosarcoma cells on repeat biopsy. This study shows that centrifugation leukapheresis is superior to filtration leukapheresis in removing significant numbers of circulating lymphosarcoma cells, though the clinical benefit of leukapheresis in this situation remains to be determined.
